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Abstract
Three types of HIV-associated neurocognitive disorders (HAND) exist that are distinguished by presence and severity of
impairment in cognitive and everyday functioning. Although well-validated neurocognitive measures exist, determining
impairment in everyday functioning remains a challenge. We aim to determine whether Self-Report measures of everyday
functioning are as effective in characterizing HAND as Performance-Based measures. We assessed 674 HIV-infected
participants with a comprehensive neurocognitive battery; 233 met criteria for a HAND diagnosis by having at least
mild neurocognitive impairment. Functional decline was measured via Self-Report and Performance-Based measures. HAND
diagnoses were determined according to published criteria using three approaches to assess functional decline: (1) Self-Report
measures only, (2) Performance-Based measures only, and (3) Dual-method combining Self-Report and Performance-Based
measures. The Dual-method classified the most symptomatic HAND, compared to either singular method. Singular method
classifications were 76% concordant with each other. Participants classified as Performance-Based functionally impaired were
more likely to be unemployed and more immunosuppressed, whereas those classified as Self-Report functionally impaired
had more depressive symptoms. Multimodal methods of assessing everyday functioning facilitate detection of symptomatic
HAND. Singular Performance-Based classifications were associated with objective functional and disease-related factors;
reliance on Self-Report classifications may be biased by depressive symptoms. (JINS, 2012, 18, 79–88)
Keywords: HIV/AIDS, Cognition disorders, Activities of daily living, Infectious disease, Self assessments, Employment
INTRODUCTION
Despite advances in antiretroviral therapy (ART), HIV-associated
neurocognitive disorders (HAND) are still observed in close to
half of the HIV-infected (HIV1) population (Heaton et al.,
2010). In the context of assigning HAND diagnoses for HIV1
persons, guidelines were recently updated to include additional
operationalization of the diagnostic criteria for daily functioning
decline (Antinori et al., 2007). More specifically, the current
nomenclature for diagnosing asymptomatic HAND (i.e.,
Asymptomatic Neurocognitive Impairment; ANI) requires
neurocognitive deficits in at least two ability domains that are
attributable to HIV-infection, but do not meaningfully influence
daily functioning (Antinori et al., 2007). In contrast, ‘‘sympto-
matic’’ HAND diagnoses require significant HIV-associated
neurocognitive deficits that interfere with functional capabilities
at either a mild (i.e., Mild Neurocognitive Disorder, MND) or
moderate-to-severe (i.e., HIV-associated Dementia, HAD) level.
It is widely held that the most prevalent form of HAND is
‘‘asymptomatic,’’ or ANI (33% of the HIV1 population;
Heaton et al., 2010), meaning that the observed neurocogni-
tive impairment does not appear to affect daily functioning.
Correspondence and reprint requests to: D.J. Moore, Department of
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However, research reliably demonstrates that even mild HIV-
associated neurocognitive deficits are significantly associated
with impaired functional outcomes, ranging from poorer
antiretroviral medication adherence (Albert et al., 1995;
Benedict, Mezhir, Walsh, & Hewitt, 2000; Hinkin et al., 2002)
and employment status (Benedict et al., 2000; Heaton et al.,
1996) to general quality of life (Benedict et al., 2000) and even
mortality (Mapou et al., 1993). Such data arguably run counter
to the presumed predominance of ‘‘asymptomatic’’ HAND in
the cognitively-impaired HIV1 population and raise questions
about the typical, self-report methods for assessing asympto-
matic versus symptomatic status. Identifying the functional
assessments that best distinguish between asymptomatic and
symptomatic HAND is critical for understanding the etiology
and progression of HAND in the neuroAIDS context.
Methodologically, well-validated neurocognitive assess-
ments exist to adequately establish the presence or absence
of neurocognitive impairment. The greater challenge for
clinicians and researchers is in the determination of impair-
ment in everyday functioning. Self-report measures of daily
functioning have several advantages, including low cost,
minimal participant burden, and high face validity (Simoni
et al., 2006; Wagner & Miller, 2004). However, self-report is
susceptible to social desirability and recall inaccuracies or
bias, which may overestimate ability (Chesney et al., 2000;
Thames, Kim, et al., 2010). For example, a recent study that
examined self-report versus electronic medication monitor-
ing of antiretroviral medications found that self-report sig-
nificantly overestimated adherence rates (self-report up to
90% adherent vs. electronic monitoring 70% adherent; Lu
et al., 2008). Additionally, self-report measures are susceptible
to overestimation biases due to depressed mood; particularly in
HIV1, studies have shown that depressive symptoms, not
objective neuropsychological performance, accounts for a
majority of the variance in cognitive and functional complaints
(Rourke, Halman, & Bassel, 1999b; Thames, Becker, et al.,
2010). Performance-based measures of daily functioning, on the
other hand, can be time-intensive and require additional training
and tools to administer (Moore, Palmer, Patterson, & Jeste,
2007), and because of their standardization may not capture
differences in requirements of individual patients’ daily tasks
and activities. Yet, performance-based measures used with
HIV-infected patients have been shown to be objective and
reliable in predicting ‘‘real life’’ outcomes such as employment
status as well as medication and financial management (Heaton
et al., 2004; Thames, Kim, et al., 2010).
Previous studies have established the importance of using
multiple assessment methods (e.g., self, informant, perfor-
mance, behavioral observation) to maximize sensitivity
(Hunsley & Meyer, 2003; Meyer et al., 2001; Schwartz,
Kozora, & Zeng, 1996) and increase the quality and useful-
ness of diagnostic information; yet, this approach is infre-
quently applied in the context of HIV. Despite this, the
current guidelines for assigning HAND diagnoses do not
require both performance-based and self-report measures in
determining level of daily functioning (Antinori et al., 2007).
In practice, clinicians and researchers often rely exclusively
on self-report measures due to their convenience (e.g.,
Woods et al., 2004). Examining the utility of performance-
based measures in assessing functional status is important as
it may add unique diagnostic information that is currently
missing when only the self-report approach is applied.
Our study, therefore, aims to compare three functional
assessment approaches to determine HAND: (1) Self-Report
measures only; (2) Performance-Based measures only; and
(3) a Dual method that combines self-report plus performance-
based measures. Specifically, our goal was to assess the incre-
mental validity of the Performance-Based approach, beyond the
common practice of self-report, in determining functional status.
In particular, we aim to examine how asymptomatic HAND
classifications change with the addition of Performance-Based
measures. We use the Dual (i.e., Self-Report plus Performance-
Based) classifications as the benchmark to examine the
diagnostic sensitivity and specificity of Performance-Based
and Self-Report alone. We hypothesized that the Dual
method would detect more symptomatic HAND (i.e., MND
and HAD) as compared to the other approaches. Addition-
ally, we expected that the Performance-Based approach
would be less susceptible to depression-related reporting
bias, and more strongly associated with objective indicators
of disease status and functional outcomes.
METHODS
Participants
Six hundred seventy-four HIV-infected (HIV1) participants
were drawn from the CNS HIV Antiretroviral Therapy Effects
Research (CHARTER) study, a prospective cohort study
conducted in HIV clinics at six academic centers: Johns
Hopkins University (Baltimore, MD); Mt. Sinai School of
Medicine (New York, NY); University of California at San
Diego (San Diego, CA); University of Washington (Seattle,
WA); University of Texas Medical Branch (Galveston, TX);
Washington University (St. Louis, MO; see Heaton et al., 2010).
All participants were HIV-infected and were excluded only if
they could not complete the assessment at the time of evalua-
tion. As the purpose of this study was to examine HAND
diagnoses, only those individuals with neurocognitive impair-
ment at entry were considered for inclusion in the analyses
(44% of the cohort; 299/674). Of these, most (45%, 135/299)
were classified as having none or minimal comorbidities
(non-HIV-related factors that could affect cognition and func-
tioning) and 33% (98/299) with moderate comorbidities. Those
with severe comorbidities (22%, 66/299) that precluded a
HAND diagnosis were excluded (see Table 4 of the E2 online
supplement from Antinori et al. 2007, for comorbid classifica-
tion assignment). Analyses were, therefore, focused on the 233
participants identified as having HIV-associated neurocognitive
impairment restricted to minimal or moderate comorbidities
(see Figure 1). The demographic, psychiatric, and HIV disease
and treatment characteristics of the study participants are
summarized in Table 1.
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Procedures
Standard approvals and participant consents
The Human Subjects Protection Committees of each partici-
pating institution approved the study procedures. Written
informed consent was obtained from all study participants.
Laboratory assessment
HIV infection was diagnosed by enzyme linked immunosorbent
assay with Western blot confirmation. Routine clinical chem-
istry panels, complete blood counts, rapid plasma reagin,
hepatitis C virus antibody, and CD41 T cells (flow cytometry)
were performed at each site’s Clinical Laboratory Improvement
Amendments (CLIA)-certified, or CLIA equivalent, medical
center laboratory. HIV RNA levels were measured centrally in
plasma and CSF by reverse transcriptase-polymerase chain
reaction (Roche Amplicor, v. 1.5, lower limit of quantitation
50 copies/mL). AIDS was diagnosed using available clinical
and immunologic data (defined as has having a CD4 Cell Count
, 200 cells/mL or the presence of an AIDS-indicating clinical
conditions using the CDC AIDS classification system).
Neurobehavioral examination
All participants completed a comprehensive neurocognitive
test battery, covering seven ability domains commonly affected
among HIV-infected persons: speed of information processing,
learning, memory, verbal fluency, attention/working memory,
executive functioning and motor (see Heaton et al., 2010,
Fig. 1. CONSORT flow chart indicating participant selection procedure; boxes in bold signify those subjects included
in analyses. *Does not add up due to rounding error.
Table 1. Demographic and clinical characteristics (n5 233)
Demographic variable M, P, or Median SD or IQR Range
Age, years 45.2 8.5 22–69
Education, years 13.3 2.4 7–20
Gender (M) 77% – –
Ethnicity
Caucasian 44% – –
African-American 39% – –
Hispanic 14% – –
Other 3% – –
Current CD4 (cells/mL) 451 168–626 –
Nadir CD4 (cells/mL) 150 43–275 –
AIDS 64% – –
% HIV CSF viral load detectable 25% – –
% detectable if on ARVs 56% – –
% HIV plasma viral load detectable 46% – –
% detectable if on ARVs 73% – –
Hepatitis C virus co-infection 23% – –
Beck Depression Inventory-II 12.6 11.1 0–56
Employed 33% – –
LT substance abuse/dependence dx 67% – –
M5mean; P5 percent; SD5 standard deviation; IQR5 Inter-quartile range; ARVs5 antiretrovirals; LT substance abuse/dependence
dx5DSM-IV diagnosis of lifetime substance abuse or dependence
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for listing of specific tests). All participants completed three
neurocognitive testing visits (screening, baseline, and 6-month
follow-up). At the screening visit, participants were adminis-
tered a subset of the larger neurocognitive battery (i.e., Hopkins
Verbal Learning Test-Revised, WAIS-III Symbol Digit, and
Grooved Pegboard). Alternate forms of the Hopkins Verbal
Learning Test-Revised and Brief Visual Memory Test-Revised
were used at each visit. Raw test scores were converted
to demographically-corrected standard scores (T-scores).
Comprehensive normative standards were used, which correct
for effects of age, education, sex and ethnicity, as appropriate
(Heaton, Taylor, Manly & Tulsky, 2003; Heaton et al., 2004;
Norman et al., 2011). We used published practice effect
corrections to adjust for a single previous exposure to the
neurocognitive tests (Cysique et al., 2011). Specifically, the
median practice effect (in scaled score units) for the group
(individual baseline performance minus 6-month follow-up
performance) was subtracted from the scaled score at the
6-month follow-up, to estimate what the performance would
have been without practice (see Cysique, Franklin, et al., 2011,
Methods: ‘‘Computation of the practice effect’’; see also further
validation of the method in a recent study of neuroAIDS in
China: Cysique, Letendre, et al., 2011). To classify presence and
severity of neurocognitive impairment, we applied a published
objective algorithm that has been shown to yield excellent
interrater reliability for HAND diagnoses in previous multisite
studies (see Woods et al., 2004). Briefly, neuropsychological
clinical ratings were assigned from demographically adjusted
T-scores for each of the seven major ability areas using a
nine-point scale (15 above average functioning, TZ55;
95 severe impairment, T , 20) with a global rating of five or
above indicating definite mild neuropsychological impairment
(see Heaton et al., 2004 and Woods et al., 2004 for details).
Consistent with the most recent and widely accepted diagnostic
guidelines (i.e., Antinori et al., 2007), two neurocogitive
domains were required to be in the impaired range to assign an
impaired global rating (Z5).
Psychiatric examination
Psychiatric and substance abuse or dependence Diagnostic
and Statistical Manual-IV diagnoses were assessed by
administering the Depression and Substance Use modules of
the computer-assisted Composite International Diagnostic
Interview (CIDI; World Health Organization, 1997). Current
mood was assessed with the Beck Depression Inventory-II
(Beck, Steer, & Brown, 1996).
Functional Impairment in Everyday Life
Self-report measures
The Patient’s Assessment of Own Functioning Inventory was
administered to determine perceived everyday functioning
impairments (PAOFI; Chelune, Heaton, & Lehman, 1986).
The PAOFI is a 41-item questionnaire in which the partici-
pant reports the frequency with which he/she has difficulties
with memory, language and communication, use of his/her
hands, sensory-perception, higher level cognitive and intel-
lectual functions, work, and recreation.
To assess dependence in performing instrumental activities
of daily living (IADLs), a modified version of the Lawton and
Brody scale was used (Heaton et al., 2004). Eleven items
were included from this scale detailing the degree to which
individuals independently function in the areas of Financial
Management, Home Repair, Medication Management, Laundry,
Transportation, Grocery Shopping, Shopping, Housekeeping
(Cleaning), Cooking, Work, and Telephone Use. For each
activity, the participant separately rates his/her current level of
independence and highest previous level of independence. The
total score is the total number of activities for which there is
currently a need for increased assistance (ranging from minimal
to complete assistance), with a range of zero (no change) to 11
(increased dependence in all activities).
Performance-based measures
Medication management was assessed via a revised version of
The Medication Management Test (MMT; Albert et al., 1999).
A full description of our modified version of the MMT
(i.e., MMT-R) can be found in Heaton et al. (2004). Briefly,
the MMT-R retains the pill-dispensing component in which
subjects must dispense a 1-day dosage of ‘‘medications’’ from
three standardized bottles labeled with dosing information. In
the medication inference component, there are seven questions
regarding the medications as well as an over-the-counter medi-
cation insert. The MMT-R takes approximately 10 minutes to
administer and the best score possible is 10 points.
Participants also completed standardized work samples
(MESA SF2) and the next generation COMPASS programs
(Valpar International Corporation, 1986, 1992). These
batteries consist of multi-modal, criterion-referenced instru-
ments designed to establish participant skill level in areas of
vocational functioning. The battery takes approximately 1 hr
and includes computerized subtests and noncomputerized
mechanical tasks that correspond to the Dictionary of Occupa-
tional Titles (DOT; U.S. Department of Labor, 1991) job levels.
Raw scores from these tests are converted into ability levels for
each of the DOT classifications using the commercial software
accompanying the MESA SF2 and COMPASS. A detailed
explanation of test development for the MESA and COMPASS
is beyond the scope of this study (see Valpar International
Corporation, 1986, 1992; Heaton et al., 2010).
Performance-based measure cut-points
Since published demographically-adjusted normative stan-
dards are not available for the performance-based tests, we
derived cut-points for the MMT-R and Valpar from the
HIV1, neuropsychologically normal subset of CHARTER
participants [n5 375; mean age5 43.4 (8.5) years;
80% male; 42% Caucasian; mean education5 12.5 years].
Based on prior studies (e.g., Heaton et al., 2004), cut-points
were determined based on a normal distribution so that 16% of
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the neuropsychologically normal cohort would be impaired at
one standard deviation (cutoff scores: MMT-R ,5 and Valpar
,24) and 2% of the cohort would be impaired at two standard
deviations (cutoff scores: MMT-R,2 and Valpar ,17).
HAND classifications
For the purposes of this study, the authors created data-driven
formulas to diagnose ANI, MND and HAD three distinct ways:
(1) using only the Self-Report measures of daily functioning;
(2) using only the Performance-Based measures of daily
functioning; and (3) a Dual method that combines both the
self- and performance-based measures of daily functioning. In all
formulas, a neuropsychological global rating score of 5 or 6
defined mild-to-moderate cognitive impairment (i.e., minimum
criteria needed for ANI or MND; see Figure 2) and a neuro-
psychological global rating score of 7 or above defined
moderate-to-severe cognitive impairment (i.e., minimum criteria
needed for HAD). Additionally, employment status that was
associated with cognitive decline (i.e., participant endorsed both
‘‘I no longer am able to work’’ and ‘‘I feel that the difficulties
I am having on the above tasks are due to: Primarily cognitive
problems’’ or ‘‘Equally cognitive and physical problems’’ on
the IADL) counted as one area of functional decline in all
formulas in accordance with the Frascati criteria (Antinori et al.,
2007). To determine functional decline in the Self-Report
formula, scores on the PAOFI and IADL were examined.
Specifically, impairment on the PAOFI was established accord-
ing to the guidelines outlined by Woods et al. (2004) such that the
presence of three or more items endorsed as ‘‘almost always,’’
‘‘very often,’’ or ‘‘fairly often’’ indicated areas of functional
impairment. To control for depression in self-report, previously
defined criteria were used (Woods et al., 2004) in which subjects
with elevated BDI scores (BDIZ17) needed to exhibit a higher
level of complaint on the PAOFI (PAOFIZ10 complaints) to
qualify for functional impairment on this measure. Scores on the
IADL that show decline from ‘‘best’’ to ‘‘now’’ in two or more
areas that were identified as being at least partially due to
cognitive problems (vs. physical impairment) also qualified
as one area of functional decline in the Self-Report formula
(Woods et al., 2004).
In the Performance-Based formula, mild and major func-
tional impairment were defined as scores one or two standard
deviations below the mean, respectively, on the MMT-R
and Valpar in line with the Frascati criteria. Therefore, MND
was diagnosed (1) if both MMT-R and Valpar scores were
one standard deviation below the mean; or (2) if one task was
one standard deviation below the mean and the subject was
unemployed. HAD was diagnosed: (1) if both MMT-R and
Valpar scores were two standard deviations below the mean;
(2) if scores on both tasks were one standard deviation below
the mean and the subject was unemployed; or (3) if one task
was two standard deviations below the mean and the subject
was unemployed.
All diagnostic criteria for functional decline were included
in the Dual diagnostic method. Measures included in each
formula criterion are summarized in Table 2.
Discrepancy variable
Discordant classifications between the Self-Report and
Performance-Based methods were examined by creating a
‘‘discrepancy variable’’ with four levels: (1) agree: asymp-
tomatic (i.e., ANI); (2) agree: symptomatic; (3) discrepant:
functionally impaired by Self-Report only; and (4) dis-
crepant: functionally impaired by Performance-Based only.
The discrepancy variable was used to examine potential
demographic, disease, psychiatric, and cognitive differences
that may be associated with discordant diagnoses.
Statistical Analyses
The McNemar-Bowker nonparametric test for non-independent
samples was conducted to compare HAND diagnosis frequencies
Fig. 2. HAND classification flow chart via the self-report, performance-based, and dual assessment approaches.
NCI5 neurocognitive impairment; ANI5 asymptomatic neurocognitive impairment; MND5mild neurocognitive
disorder; HAD5HIV-associated dementia; Mild-to-moderate NCI: global rating5 5 or 6; Moderate-to-severe NCI5
global ratingZ 7.
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(i.e., ANI vs. MND. vs. HAD) as well as ‘‘symptomatic’’ fre-
quencies (i.e., MND or HAD) across each diagnostic method.
Sensitivity and specificity of the singular methods (i.e.,
Self-Report and Performance-Based) compared to the Dual
method were calculated for each diagnostic level (i.e., ANI
vs. MND1HAD; ANI1MND vs. HAD; and ANI vs. MND).
w2 analyses were conducted to compare the sensitivity and
specificity of the Self-Report versus Performance-Based
methods across each specified diagnostic level.
The discrepancy variable (described above) was explored by
screening which disease and functional variables significantly
predicted the discrepancy variable at a 10% significance level
in a multivariable logistic regression. Only those variables
remaining were again entered together in the multivariable
logistic regression with discrepancy variable as the outcome.
Each of the variables remaining in the model were then tested
individually for differences between the ‘‘only Performance-
Based functionally impaired’’ and the ‘‘only Self-Report func-
tionally impaired’’ levels of the discrepancy variable.
Additional analyses explored the relationship between
scores on the individual Self-Report and Performance-Based
measures to self-reported depressive symptoms (i.e., BDI-II)
using nonparametric Spearman’s correlations.
RESULTS
HAND Frequencies Across Self-Report,
Performance-Based and Dual Methods
As shown in Figure 3, the Dual method yielded the lowest
prevalence of ANI diagnoses at 59% as compared to 83% with
the Performance-Based method (w25 56; p, .001) and 76%
with the Self-Report approach (w25 39; p, .001). Addition-
ally, the Performance-Based method classified more partici-
pants as ANI than the Self-Report approach (w25 5.1, p5 .02).
The Dual approach detected the most MND classifications at
36% as compared to 17% with the Performance-Based method
(w25 39.2; p, .001), and 20% with the Self-Report method
(w25 38; p, .001). The Performance-Based method yielded
the least number of HAD diagnoses at 0.009% (n5 1)
compared to Self-Report (w25 9; p5 .003) and the Dual
method (w25 10; p5 .002), which were comparable in
their number of HAD diagnoses at 4% and 5%, respectively.
Among the symptomatic diagnoses, there was an additive
effect between each of the singular diagnoses (Self-
Report5 24% and Performance-Based5 17% symptomatic)
to comprise the Dual diagnoses (i.e., 41%) suggesting that there
are not many overlapping symptomatic diagnoses across each
of these singular methods.
Sensitivity and Specificity of the Singular Methods
Compared to the Dual Method
Using the Dual method as the ‘‘benchmark’’ to compare the
singular methods against, the Performance-Based and Self-
Report diagnoses had comparable sensitivity in detecting MND
versus ANI classifications (42.7% vs. 57.3% respectively;
w25 2.2; p5 .14). The Performance-Based method was also
comparably sensitive to the Self-Report method in determining
symptomatic (i.e., MND1HAD) versus asymptomatic (i.e.,
ANI diagnoses) (41.2% vs. 58.8% respectively; w25 3.8;
p5 .052). However, the Self-Report method was more sensi-
tive in detecting HAD versus ANI1MND (i.e., non-HAD)
diagnoses than the Performance-Based method (90.9% vs.
9.1%; w25 7.5; p5 .006). Specificity (i.e., proportion of indi-
viduals that are correctly identified as functionally unimpaired)
Table 2. Criteria for measures included in each diagnostic formula
Formula NP Global Rating PAOFI IADL MMT-R Valpar
Self-Report Z 55 cognitive impairment Z 3 elevated items Z 2 areas of decline
Performance-Based Z 55 cognitive impairment , 55mild imp; , 245mild imp;
, 25mod imp , 175mod imp
Dual method Z 55 cognitive impairment Z 3 elevated items Z 2 areas of decline , 55mild imp; , 245mild imp;
, 25mod imp , 175mod imp
NP5neuropsychological; PAOFI5Patient’s Assessment of Own Functioning Inventory; IADL5 Instrumental Activities of Daily Living; MMT-R5
Medication Management Test-Revised; mild imp5mild impairment (below 1 SD); mod imp5moderate impairment (below 2 SDs). Note: employment status
was also included in the diagnostic formulas and additional modifications were made for individuals with significant depression, see text.
Fig. 3. The Dual classification method yielded the lowest
prevalence of ANI and largest prevalence of symptomatic diagnoses
compared to either singular method. Each row represents the
proportion of specific HAND diagnoses by assessment method
among the participants with HIV-associated neurocognitive impair-
ment. NCI5 neurocognitive impairment; ANI5 asymptomatic
neurocognitive impairment; MND5mild neurocognitive disorder;
HAD5HIV-associated dementia.
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across all of the different HAND levels was comparable
between the Self-Report and Performance-Based methods
(MND vs. ANI: 51.6% vs. 48.3%; and MND1HAD vs. ANI:
52.3% vs. 47.7%; HAD vs. ANI1MND: 51.0% vs. 49.0%;
p’s. .05).
Discrepant Singular Diagnoses
When examining the discrepancy variable (i.e., discordant
singular classifications) across demographic and clinical
variables of interest, age, ethnicity (Caucasian vs. other),
education, current CD4, HCV status, BDI-II, and employment
status predicted the discrepancy variable at the p, .10 level.
In a multivariable analysis, all of these predictor variables
uniquely contributed to discrepant diagnoses except edu-
cation and HCV status (see Table 3). Specifically, the
Performance-Based functionally impaired participants were
less likely to be Caucasian (w25 10.5; p5 .001), less likely
to be employed (w25 9.1; p5 .003), endorsed fewer
depressive symptoms (w25 7.6; p, .006), and had lower
current CD4 counts (w25 11.6; p, .001) than the Self-Report
functionally impaired individuals. See Figure 4 for discrepant
diagnosis frequencies. Although age was a significant predictor
of the discrepancy variables in the omnibus multivariable test,
pairwise analyses did not indicate any group differences across
the individual levels of the discrepancy variable (p’s. .05).
Within the concordant diagnoses between the singular
methods, the asymptomatic agreement group endorsed fewer
depressive symptoms (w25 17.3; p, .001) and was more
likely to be employed (w25 11.4; p, .001) than the symp-
tomatic agreement group, as expected.
Depression
As depressive symptoms have been shown to be highly
associated with functional status and can particularly influence
self-reported functioning (Rourke, Halman, & Bassel, 1999b;
Thames, Becker, et al., 2010), we examined the relationship of
Beck Depression Inventory-II scores to all of the functional
measures. Both of the Self-Report measures were correlated to
BDI-II scores (IADL: r5 0.44; p, .001; PAOFI: r5 0.54;
p, .001). Neither of the Performance-Based measures was
correlated to BDI-II scores (Valpar: r520.01; p5 .74; MMT-R:
r50.007; p5 .87).
DISCUSSION
Findings from this study indicate that multimodal assessment
of functional status better detects symptomatic HAND as
compared to singular methods of ascertainment. This is
congruent with other research that has established the incre-
mental value of incorporating information from multiple
sources in determining diagnoses (Meyer et al., 2001; Schwartz
et al., 1996). A moderate (76%) concordance existed between
the Self-Report and Performance-Based methods in classifying
functional impairment. Of the two methods, Self-Report clas-
sified more participants as having major functional impairment
(i.e., HAD), however, 9% of the sample was classified as
impaired via Performance-Based but not Self-Report. Our only
objective indicator of everyday functioning was employment
status, and individuals who were classified as functionally
impaired only by Performance-Based were more likely to be
Table 3. Multivariable logistic regression model predicting four-level
discrepancy variable: 1) agree: asymptomatic; 2) agree: symptomatic;
3) discrepant: functionally impaired by Self-Report only; 4) discrepant:
functionally impaired by Performance-Based only.
Variable w2 p value
Step 1: Multivariable logistic regression model.
Overall model: R25 0.27, w25 102.9, p, .001
Agey 6.8 .08
Ethnicity (Caucasian vs. other) y 6.8 .08
Educationy 6.9 .08
Gender 0.80 .85
Current CD4y 8.5 .04
AIDS 0.55 .91
Log10 HIV RNA (CSF) 2.9 .41
Log10 HIV RNA (plasma) 2.7 .43
HCV statusy 6.8 .08
BDI-IIy 27.9 , .001
LT substance abuse/dependence 4.4 .21
Employmenty 20.3 , .001
Global NP T-score 0.37 .95
Step 2: Multivariable logistic regression model with significant
(p,.10) predictors.




Current CD4* 14.6 .002
HCV statusy 6.30 .10
BDI-II* 28.8 , .001
Employment* 18.0 , .001
yp, .10; *p, .05.
HCV5Hepatitis C co-infection; BDI-II5Beck Depression Inventory-II;
LT5 lifetime; NP5 neuropsychological.
Fig. 4. Frequency of discrepant Self-Report versus Performance-
Based classifications. Agree: No functional impairment5 67%
(156/233); Agree: Functional impairment5 9% (20/233); Discre-
pancy: Impaired by Self-Report only5 16% (37/233); Discrepancy:
Impaired by Performance-Based only5 9% (20/233). Abbrevia-
tions: NCI5 neurocognitive impairment.
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unemployed than those who were called functionally impaired
only by Self-Report. In addition, participants impaired only on
the Performance-Based approach had more immunosuppres-
sion. These findings support the validity of the Performance-
Based measures in addition to the Self-Report measures in
being able to detect ‘‘real life’’ constructs that are theoretically
important to functional status.
Importantly, the prevalence of ANI changed from 76%
using only Self-Report to 59% using the Dual Self-Report
plus Performance-Based approach. This finding demonstrates
that individuals classified as ANI via traditional Self-Report
assessments may not be as ‘‘asymptomatic’’ as they are report-
ing, thereby inflating the prevalence rates of ANI. Instead,
participants who were classified as functionally impaired by
Self-Report only showed more depressive symptoms, which are
known to be associated with negative self-image and a tendency
to over-report functional impairment (Rourke et al., 1999b;
Thames, Becker, et al., 2010). Depressive symptoms were to
some extent accounted for in the Self-Report classification in
that those individuals with elevated depressive symptom scores
(BDI-IIZ17) need to have substantially more complaints
(PAOFIZ10) to meet HAND criteria. Therefore, despite a
restricted BDI-II range, the effect of mild depression was still
captured in the Self-Report diagnoses. The influence of
depressive symptoms in the Self-Report classifications that is
absent in the Performance-Based classifications illustrates the
powerful interrelationship between depressive symptoms and
complaints and, subsequently, how a belief of impairment can
influence diagnosis. The potential impact of depressive symp-
toms in determining self-reported functional status highlights
the importance of taking affective state into account when
determining HAND classifications based on self-report.
On the other hand, since those individuals classified as
functionally impaired only by Self-Report appeared to have
more functionally complex lives (i.e., more likely to be
employed and less disease severity), the importance of any
decline may have impacted the number and severity of
reported complaints relative to expectations in their lives. In
other words, those with the most complicated lives had the
most to lose functionally and were, therefore, more likely to
complain of these changes. Self-report measures inherently
control for variables relative to individual (e.g., perceived
premorbid functioning and life expectations), and, therefore,
reflect the individual’s inability to complete tasks specific to
his or her own life. Although Performance-Based measures
do not account for the subjective relevance of functional
decline, they do standardize impairment so that individual
performances can be equally compared to each other. In this
manner, the Performance-Based approach provides a stan-
dard diagnostic of impairment for each HAND level thereby
improving the ability for clinicians and researchers to com-
municate with common understanding.
An important limitation of the current study is the use of
the Dual diagnostic method to compare the singular methods
when the Dual method is just a composite of both of the
singular methods together. As such, an association between
the singular and dual methods is anticipated, and the true
sensitivity and specificity of each of the singular methods to
real life HAND diagnoses is not clear. Ideally, the Self-
Report and Performance-Based methods should be compared
to an independent measure of daily functioning, such as a
clinician’s rating, informed proxy report, or an objective
outcome measure (e.g., medication blood levels as an indi-
cator of adherence). Additionally, it is important to note that
each of the three formulas for HAND classifications were
purely data-driven––clinical input is an integral aspect in
determining HAND diagnoses and should always be incor-
porated in addition to the available data. Another potential
limitation of our study is the use of the PAOFI to assess Self-
Reported functional aptitude. The PAOFI addresses several
cognitive skills in relation to daily functioning [e.g., ‘‘Do you
have more difficulty now than you used to in calculating
or working with numbers? (including managing finances,
paying bills, etc.)’’], and as such tend to emphasize patients’
cognitive complaints rather than functional complaints;
however, the PAOFI is a widely used assessment in assign-
ment of HAND diagnoses as well as HIV-related functional
declines in a large consortium of research (e.g., Heaton et al.,
2004, 2011; Joska et al., 2011; Woods et al., 2004; Woods,
Moore, Weber, & Grant, 2009). Lastly, the use of the Valpar/
COMPASS program to evaluate everyday functioning may
be considered a limitation of the current study given that
several of the subtests included may not appear to be face
valid for many jobs (e.g., threading a needle through a board);
as such, these results should be interpreted accordingly.
Nevertheless, the Valpar/COMPASS program as a whole has
been designed to map onto Department of Labor determina-
tions of requirements of jobs in the U.S. economy and has
been used in previous studies to classify HIV-related func-
tional impairment (e.g., Heaton et al., 2004; Twamley et al.,
2006; Wright, Woo, Barclay, & Hinkin, 2009).
To summarize, findings from this study indicate that
incorporating information from functional Performance-
Based measures in addition to the traditional Self-Report
approach detects more symptomatic impairment; using either
Self-Report or Performance-Based measures alone classifies
less functional impairment. In particular, use of only tradi-
tional functional Self-Report measures yields significantly
higher rates of ANI compared to the Dual method. These
findings support the commonly observed, and perhaps dis-
proportionally, high levels of ‘‘asymptomatic’’ HAND reported
in clinical studies when only self-report measures of functional
impairment are used. Although Self-Report measures allow
individuals to anchor their functional difficulties specific to the
demands in their own daily lives, self-reported functional
complaints appear to be significantly influenced by depressive
symptoms. On the other hand, Performance-Based measures
standardize deficits onto a comparable scale and, importantly,
may be most predictive of true disease and functional status;
this is supported by greater associations with employment and
degree of current immunosuppression. Another benefit of the
Performance-Based approach is the measures’ lack of rela-
tionship to depressive symptoms. As such, we suggest that
Performance-Based measures are a useful and valid component
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of functional assessments, which are likely to enhance the
accuracy of symptomatic HAND classifications (beyond Self-
Report only). Of note, however, Performance-Based measures
do take more time and training than Self-Report which may not
be practical in many clinical settings; nonetheless, clinicians
and researchers should be aware that use of Self-Report only is
likely to both underclassify symptomatic HAND and result in
some false positive diagnoses due to depression-related biases
in self-evaluations.
Overall, when assessing functional status, our findings
support the time and resources necessary to incorporate
Performance-Based measures in addition to the traditional
Self-Report method in individuals with HIV. The current
study uses a comprehensive approach in identifying HAND,
which allows for objective evaluation of the best approach to
define this phenomenon; however, the ultimate goal, particu-
larly for clinicians, would be to establish brief, performance-
based assessments that are able to capture those individuals
identified as functionally impaired in a quicker manner. Our
study helps identify a targeted battery for detecting HAND (i.e.,
inclusion of both Self-Report and Performance-Based func-
tional measures), yet future studies are necessary to validate a
brief battery including a combination of these assessments to be
used clinically.
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